NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded the stock of BioMérieux, following its announcement two days ago that it will acquire BioFire Diagnostics.

The investment bank upgraded the French in vitro diagnostic firm to Overweight from Neutral, and increased the price target on its stock to €86 ($113.20) from €71.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.